Switching from donepezil or rivastigmine to galantamine in clinical practice

被引：8
作者：
Edwards, K [1 ]
O'Connor, JT [1 ]
Gorman, C [1 ]
机构：
[1] Neurol Res Ctr, Alzheimers Dis & Treatment Ctr, Bennington, VT 05201 USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2004年 / 52卷 / 11期
关键词：
D O I：
10.1111/j.1532-5415.2004.52529_3.x
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：1965 / 1965
页数：1
相关论文
共 5 条
[1]   Use of cholinesterase inhibitors in clinical practice - Evidence-based recommendations [J].
Cummings, JL .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 11 (02) :131-145
[2]   Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease [J].
Doody, RS ;
Geldmacher, DS ;
Gordon, B ;
Perdomo, CA ;
Pratt, RD .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :427-433
[3]   Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors [J].
Gauthier, S ;
Emre, M ;
Farlow, MR ;
Bullock, R ;
Grossberg, GT ;
Potkin, SG .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (08) :707-714
[4]   EFFECTS OF ACUTE SUBCUTANEOUS NICOTINE ON ATTENTION, INFORMATION-PROCESSING AND SHORT-TERM-MEMORY IN ALZHEIMERS-DISEASE [J].
JONES, GMM ;
SAHAKIAN, BJ ;
LEVY, R ;
WARBURTON, DM ;
GRAY, JA .
PSYCHOPHARMACOLOGY, 1992, 108 (04) :485-494
[5]   Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors [J].
Samochocki, M ;
Höffle, A ;
Fehrenbacher, A ;
Jostock, R ;
Ludwig, J ;
Christner, C ;
Radina, M ;
Zerlin, M ;
Ullmer, C ;
Pereira, EFR ;
Lübbert, H ;
Albuquerque, EX ;
Maelicke, A .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :1024-1036
1